A clinical-stage biopharmaceutical company focused on developing novel therapeutic medicines for the treatment of cystic fibrosis (CF) by targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Waltham, MA, United States~59 employeesFounded Jan 2019Website